NCT03454737UnknownNot Applicable
Treatment of Refractory Patellar Tendinopathy With Mesenquimal Trunk Cells. Comparative Study With PRP.
Institut de Terapia Regenerativa Tissular2 sites in 1 country20 target enrollmentStarted: December 13, 2017Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 20
- Locations
- 2
- Primary Endpoint
- Improvement in the tendon ecotexture
Study Overview
Brief Summary
This is a clinical trial, unicentric, prospective, controlled, randomized, double blind during the experimental phase A.
In the experimental phase B, it is contemplated to administer the experimental treatment to the subjects included in the group treated with P-PRP in the event that the first treatment would be significantly more effective, both from a clinical and regenerative point of view
Detailed Description
- Main objective
- Confirm the presence of patellar tendon gap regeneration after the peritendinous and intratendinous infusion of MSV and compare it with the P-PRP group, evaluated by ECO, NMR and UTC.
- To evaluate the clinical efficacy of infusion of MSC in refractory patellar tendinopathy compared with the P-PRP group through the subjective clinical evolution of the patient, the EVA and VISA-P questionnaires and the strength of the extensor muscle group measured by dynamometry.
- Secondary objective 1. To evaluate the feasibility and safety of the advanced therapy medication MSV and P-PRP when applied by percutaneous infusion into the body of the patellar tendinosis, verifying that each of the procedures established in the protocol is feasible and recording the possible adverse effects related with both treatments and adverse events arising during the period of the clinical trial, whether or not related to it
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 48 Years (Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male sex with ages between 18 and 48 years.
- •Pain in the patellar tendon, located in the patellar insertion area, of more than 4 months of duration that does not show significant improvement after conservative treatments such as rest, analgesia, physiotherapy and / or infiltration.
- •Ultrasound image that confirms, both static and dynamic, the loss of the fibrillar structure of the proximal part of the patellar tendon, its thickening and a hypoechoic lesion compatible with gap ≥3mm.
- •MRI of the patellar tendon in T2 FAT SAT sequence (fat saturation) that shows a gap ≥3mm in longitudinal diameter in the proximal insertion.
- •Informed Consent in writing and signed by the patient.
- •The patient is able to understand the nature of the study.
Exclusion Criteria
- •Patient under 18 years of age (or legally dependent) and over 48 years of age.
- •MRI with grade III-IV intra-articular pathology of all compartments of the knee and / or cruciate ligament injury
- •Local treatment with corticosteroids during the last year
- •Local treatment with PRP during the last 6 months.
- •Present infection (no local or systemic infectious signs should be evidenced).
- •Patients presenting positive serology in front of:
- •HIV 1 and 2, Hepatitis B (HBsAg, HBcAc), Hepatitis C (Anti-HCV-Ab), Lúes.
- •Congenital or evolutive diseases that translate malformation and / or significant deformations of the knee and condition difficulties of application and evaluation of the results.
- •Weight overload expressed in body mass index (BMI) greater than 30.5 (obesity grade II). Being BMI = mass (Kg): (height (m)) 2
- •Active neoplastic disease.
- •Active immunosuppressive states.
- •Simultaneous participation in another clinical trial or treatment with another product in the Research phase in the 30 days prior to inclusion in the study.
- •Other pathologies or circumstances that compromise participation in the study according to medical criteri
Arms & Interventions
mesenchymal stem cells
Experimental
Intervention: mesenchymal stem cells (Procedure)
Pure platelet-rich plasma
Active Comparator
Intervention: Pure platelet-rich plasma (Procedure)
Outcomes
Primary Outcomes
Improvement in the tendon ecotexture
Time Frame: 24 months
The patellar tendon will be examined longitudinally and transversely using gray scale and color, exerting a minimum pressure with the probe. Images will be recorded in static and dynamic formats to develop a consensus of the findings.
Secondary Outcomes
- the strength of the extensor muscle group(24 months)
- Presence of patellar tendon regeneration by the peritendinous and intratendinous infusion of MSV patellar tendinopathy compared to the P-PRP group(24 months)
- subjective clinical evolution of the patient(24 months)
- strength of the extensor muscle group(24 months)
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Withdrawn
Phase 2
A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar TendinopathyTendinopathyNCT02597660Hospital for Special Surgery, New York
Active, not recruiting
Phase 1
Treatment of Refractory Patellar Tendinopathy with MSV. Comparative study with P-PRPPatients diagnosed with patellar tendinopathy with a minimum of 4 months evolution and have presented two acute episodes, refractory to standard treatments present a gap equal or greater than 3 mm at rest.MedDRA version: 20.0Level: LLTClassification code 10034123Term: Patellar tendinitisSystem Organ Class: 100000004859EUCTR2016-001262-28-ESInstitut de Terapia Regenerativa Tissular S.L. (ITRT)
Completed
Phase 1
Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus InfectionOral Herpes SimplexNCT01308424Beech Tree Labs, Inc.171
Terminated
Phase 4
Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.Urinary Urge IncontinenceNCT02176642Duke University55
Terminated
Phase 2
A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From OsteoarthritisPainArthralgiaJoint PainOsteoarthritis, KneeOsteoarthritisNCT01094262Johnson & Johnson Pharmaceutical Research & Development, L.L.C.196